Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

Trastuzumab (Herceptin(®)), a humanized IgG1 antibody raised against the human epidermal growth factor receptor 2 (HER2/neu), is the main antibody in clinical use against breast cancer. Pre-clinical evidence and clinical studies indicate that trastuzumab employs several anti-tumour mechanisms that m...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Karagiannis, Panagiotis, Singer, Josef, Hunt, James, Gan, Samuel K. E., Rudman, Sarah M., Mechtcheriakova, Diana, Knittelfelder, Regina, Daniels, Tracy R., Hobson, Philip S., Beavil, Andrew J., Spicer, James, Nestle, Frank O., Penichet, Manuel L., Gould, Hannah J., Jensen-Jarolim, Erika, Karagiannis, Sophia N.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3017872/
https://ncbi.nlm.nih.gov/pubmed/18941743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-008-0607-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia